Therefore, the proteins identified in the nuclear fraction of HL-60 cells that also harbor the deletion of the p53 gene may be potential targets for the development of alternative methods of AML (non-APL types) therapy. The gene discussed is TP53; the disease is acute myeloid leukemia.